Back to Awarded Treatment Trials
Awarded Trial: 02T-251
Grant ID
02T-251
Illness
Schizophrenia
Primary Drug/Intervention
Pimozide
Primary Dosage
2mg-8mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Gunduz-Bruce
Sample Size
60
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
BPRS, SANS, AIMS, Simpson-Angus, Modified Barnes Akathisia Scale, cognitive battery
Results
Pimozide or placebo were used as augmentation for 32 schizophrenia patients partially responsive to clozapine for 12 weeks. 28 completed the trial. There were no significiant differences on BPRS, SANS, or the psychosis or depression subscales but it did have a significant effect on verbal working memory (digit span).
Publication
Being submitted.
Link
N/A
PI Name
Handan Gunduz-Bruce
Degree
MD
Center
VA CT Healthcare System
Institution
Yale University School of Medicine
Address
950 Campbell Ave
City or Town
West Haven
State or Province
CT
Zip or Postal Code
6516
Country
USA
Email Address
handan.gunduz-bruce@yale.edu